{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:54Z","timestamp":1792740774631,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2020,3,13]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Alterations in dopamine neurotransmission underlie some of the clinical features of Huntington\u2019s disease (HD) and as such are a target for therapeutic intervention, especially for the treatment of chorea and some behavioural problems. However, justification for such an intervention is mainly based on case reports and small open label studies and the effects these drugs have on cognition in HD remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we used the Enroll-HD observational database to assess the effects of antidopaminergic medication on motor, psychiatric and cognitive decline, over a 3-year period. We first looked at the annual rate of decline of a group of HD patients taking antidopaminergic medication (n=466) compared with an untreated matched group (n=466). The groups were matched on specified clinical variables using propensity score matching. Next, we studied a separate group of HD patients who were prescribed such medications part way through the study (n=90) and compared their rate of change before and after the drugs were introduced and compared this to a matched control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that HD patients taking antidopaminergic medication had a slower progression in chorea and irritability compared with those not taking such medications. However, this same group of patients also displayed significantly greater rate of decline in a range of cognitive tasks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion we found that antidopaminergic treatment is associated with improvements in the choreic movements and irritability of HD but worsens cognition. However, further research is required to prospectively investigate this and whether these are causally linked, ideally in a double-blind placebo-controlled trial.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2019-322038","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T21:19:43Z","timestamp":1585603183000},"page":"622-630","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington\u2019s disease (Enroll-HD)"],"prefix":"10.1136","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-4337","authenticated-orcid":false,"given":"Kate L","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"2024111108100752000_91.6.622.1","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/119.5.1633","article-title":"Executive and mnemonic functions in early Huntington's disease","volume":"119","author":"Lawrence","year":"1996","journal-title":"Brain"},{"key":"2024111108100752000_91.6.622.2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.09.007","article-title":"Task-switching abilities in pre-manifest Huntington's disease subjects","volume":"60","author":"Migliore","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"2024111108100752000_91.6.622.3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neuropsychologia.2015.02.017","article-title":"The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease","volume":"70","author":"Mason","year":"2015","journal-title":"Neuropsychologia"},{"key":"2024111108100752000_91.6.622.4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","article-title":"Neuropsychiatric aspects of Huntington's disease","volume":"71","author":"Paulsen","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024111108100752000_91.6.622.5","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"2024111108100752000_91.6.622.6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00710","article-title":"International guidelines for the treatment of Huntington's disease","volume":"10","author":"Bachoud-L\u00e9vi","year":"2019","journal-title":"Front Neurol"},{"key":"2024111108100752000_91.6.622.7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease","volume":"25","author":"Martinez-Horta","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"2024111108100752000_91.6.622.8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp.2006.103309","article-title":"Psychiatric disorders in preclinical Huntington's disease","volume":"78","author":"Julien","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024111108100752000_91.6.622.9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ana.20121","article-title":"Functional brain changes in presymptomatic Huntington's disease","volume":"55","author":"Reading","year":"2004","journal-title":"Ann Neurol"},{"key":"2024111108100752000_91.6.622.10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"2024111108100752000_91.6.622.11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/0959-4388(93)90167-W","article-title":"Basal ganglia intrinsic circuits and their role in behavior","volume":"3","author":"Mink","year":"1993","journal-title":"Curr Opin Neurobiol"},{"key":"2024111108100752000_91.6.622.12","article-title":"Tetrabenazine in the treatment of Huntington's disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2024111108100752000_91.6.622.13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0301-0082(02)00011-4","article-title":"Dopamine and the regulation of cognition and attention","volume":"67","author":"Nieoullon","year":"2002","journal-title":"Prog Neurobiol"},{"key":"2024111108100752000_91.6.622.14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cortex.2012.04.013","article-title":"Dopamine reverses reward insensitivity in apathy following globus pallidus lesions","volume":"49","author":"Adam","year":"2013","journal-title":"Cortex"},{"key":"2024111108100752000_91.6.622.15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","article-title":"Dopamine system dysregulation in major depressive disorders","volume":"20","author":"Belujon","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"2024111108100752000_91.6.622.16","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","article-title":"Inverted-U-shaped dopamine actions on human working memory and cognitive control","volume":"69","author":"Cools","year":"2011","journal-title":"Biol Psychiatry"},{"key":"2024111108100752000_91.6.622.17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","article-title":"Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes","volume":"120","author":"B\u00e4ckman","year":"1997","journal-title":"Brain"},{"key":"2024111108100752000_91.6.622.18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from Enroll-HD, a global clinical research platform for Huntington's disease","volume":"4","author":"Landwehrmeyer","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"2024111108100752000_91.6.622.19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/gps.5062","article-title":"The impact of apathy on cognitive performance in the elderly","volume":"34","author":"Montoya-Murillo","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"2024111108100752000_91.6.622.20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024111108100752000_91.6.622.21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ana.410410521","article-title":"Cag repeat number governs the development rate of pathology in Huntington's disease","volume":"41","author":"Penney","year":"1997","journal-title":"Ann Neurol"},{"key":"2024111108100752000_91.6.622.22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"2024111108100752000_91.6.622.23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"key":"2024111108100752000_91.6.622.24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024111108100752000_91.6.622.25","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.35.10.1450","article-title":"The gait abnormality of Huntington's disease","volume":"35","author":"Koller","year":"1985","journal-title":"Neurology"},{"key":"2024111108100752000_91.6.622.26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","article-title":"Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease","volume":"20","author":"Duff","year":"2008","journal-title":"Ann Clin Psychiatry"},{"key":"2024111108100752000_91.6.622.27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"2024111108100752000_91.6.622.28","first-page":"69","article-title":"Short-Term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"2024111108100752000_91.6.622.29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1152\/jn.1989.61.4.799","article-title":"Functional properties of monkey caudate neurons. II. visual and auditory responses","volume":"61","author":"Hikosaka","year":"1989","journal-title":"J Neurophysiol"},{"key":"2024111108100752000_91.6.622.30","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.6038","article-title":"Dopamine and eye movement control in Parkinson's disease: deficits in corollary discharge signals?","volume":"6","author":"Railo","year":"2018","journal-title":"PeerJ"},{"key":"2024111108100752000_91.6.622.31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JHD-150143","article-title":"Antidopaminergic medication is associated with more rapidly progressive Huntington's disease","volume":"4","author":"Tedroff","year":"2015","journal-title":"J Huntingtons Dis"},{"key":"2024111108100752000_91.6.622.32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","article-title":"Olanzapine and Huntington's disease","volume":"21","author":"Bogelman","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"2024111108100752000_91.6.622.33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington's disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N Engl J Med"},{"key":"2024111108100752000_91.6.622.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173872","article-title":"Bupropion for the treatment of apathy in Huntington's disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial","volume":"12","author":"Gelderblom","year":"2017","journal-title":"PLoS One"},{"key":"2024111108100752000_91.6.622.35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004714-199906000-00003","article-title":"Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic","volume":"19","author":"Ramaekers","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2024111108100752000_91.6.622.36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.schres.2006.03.033","article-title":"Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood","volume":"85","author":"Saeedi","year":"2006","journal-title":"Schizophr Res"},{"key":"2024111108100752000_91.6.622.37","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.neuroimage.2005.11.014","article-title":"Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge","volume":"30","author":"Vernaleken","year":"2006","journal-title":"Neuroimage"},{"key":"2024111108100752000_91.6.622.38","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington's disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"2024111108100752000_91.6.622.39","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/jnnp-2014-308153","article-title":"Modelling the natural history of Huntington's disease progression","volume":"86","author":"Kuan","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024111108100752000_91.6.622.40","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2174\/138161206777698909","article-title":"Serotonin and human cognitive performance","volume":"12","author":"Schmitt","year":"2006","journal-title":"Curr Pharm Des"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-322038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:11:53Z","timestamp":1731341513000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-322038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,15]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jnnp-2019-322038"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-322038","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}